MedTrace Logo

A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

NCT05804383 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2025-11-06

No results posted yet for this study

Summary

A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease

Conditions

Interventions

DRUG

BMS-984923

Capsules

DRUG

Placebo

Capsules

Sponsors & Collaborators

  • Yale University

    collaborator OTHER

  • National Institute on Aging (NIA)

    collaborator NIH

  • Allyx Therapeutics

    lead INDUSTRY

Principal Investigators

  • Adam Mecca, MD, PhD · Yale University

  • Stephanie Post, MD · Spaulding Clinical Research (Stage 1)

  • Adam Mecca, MD, PhD · Yale University (Stage 2)

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-28
Primary Completion
2025-07-15
Completion
2025-10-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05804383 on ClinicalTrials.gov